Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of obicetrapib with or without ezetimibe in mild dyslipidemia
2019-004935-22Phase 2Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Jul 2020
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dyslipidemia and hypercholesterolemia comparing obicetrapib + Ezetrol, obicetrapib monotherapy and placebo (3 arms). Primary endpoint: Percent change in LDL-C from Day 1 to Day 85 for combination therapy vs placebo. Started Jul 2020; status: completed.
02
Drugs
obicetrapibezetimibe
03
Conditions
dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on 2019-004935-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004935-22.